How has the darbepoetin alfa (aranesp) market evolved, and where is it heading next?
The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.81 billion in 2024 to $6.11 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to anemia treatment advancements, erythropoiesis-stimulating agents (ESAs) demand, biopharmaceutical innovation, clinical acceptance, and improved patient outcomes
The darbepoetin alfa (aranesp) market size is expected to see strong growth in the next few years. It will grow to $7.51 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to healthcare reimbursement policies, increased awareness and education, healthcare infrastructure development, renal care demands, aging population. Major trends in the forecast period include global market penetration, digital health integration, personalized treatment approaches, adoption of biosimilars, and long-acting formulations.
Get Your Free Sample of The Global Darbepoetin Alfa (Aranesp) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp
What are the key drivers behind the rapid expansion of the darbepoetin alfa (aranesp) market?
The increase in the prevalence of chronic diseases is expected to propel the growth of the darbepoetin alfa market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Darbepoetin alfa is used to treat various chronic diseases, to reverse chemotherapy-induced anemia in cancer. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based statutory authority of the Australian Government, chronic conditions were responsible for 171,500 deaths in 2022, representing 90% of all deaths, with a rate of 659 per 100,000 population. The age-standardised death rate due to chronic conditions fell to 448 per 100,000 in 2020 but increased to 459 in 2021 and 490 in 2022. Therefore, an increase in the prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.
What is the segmentation for the darbepoetin alfa (aranesp) market?
The darbepoetin alfa (aranesp) market covered in this report is segmented –
1) By Type: Epogen, Procrit, Aranesp, Other Types
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications
Subsegments:
1) By Epogen: Standard Formulations, Enhanced Formulations
2) By Procrit: Standard Formulations, Biosimilars
3) By Aranesp: Single-Dose Vials, Multi-Dose Vials
4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report
Who are the most influential companies in the darbepoetin alfa (aranesp) market?
Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.
What are the most influential trends expected to drive the darbepoetin alfa (aranesp) market forward?
Product innovations are a key trend gaining popularity in the darbepoetin alfa market. Major companies operating in the darbepoetin alfa market are adopting new technologies to sustain their position in the market. For instance, in February 2023, GlaxoSmithKline. Ltd., a UK-based pharmaceutical and biotechnology company, introduced the US Food and Drug Administration (FDA), a US-based government agency that approved Jesduvroq (daprodustat). Daprodustat, recombinant human erythropoietin (rhEPO, darbepoetin alfa or epoetin alfa), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor and is used once daily treatment of anemia brought on by chronic kidney disease (CKD) in people who have been on dialysis for at least four months.
What are the major regional insights for the darbepoetin alfa (aranesp) market, and which region holds the top position?
North America was the largest region in the darbepoetin alfa (Aranesp) market in 2024. The regions covered in the darbepoetin alfa (Aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Darbepoetin Alfa (Aranesp) Market Report 2025 Offer?
The darbepoetin alfa (aranesp) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Darbepoetin alfa (Aranesp) is a medication used to treat anemia brought on by chemotherapy and chronic kidney disease. It helps the bone marrow make more red blood cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12171
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
